GM3 Specific Neutra™ Antibody Products

Are you struggling with prolonged drug development timelines, inconsistent antibody specificity, or challenges in targeting glycan-mediated pathologies? Creative Biolabs' GM3-specific Neutra™ antibody products leverage advanced glycoengineering and epitope-focused immunization to deliver high-affinity, validated antibodies for precise detection, functional neutralization, and therapeutic development targeting GM3 ganglioside.

Introduction to GM3 Ganglioside

GM3 ganglioside, a sialylated glycosphingolipid, is a critical component of cell membranes, particularly enriched in lipid rafts. It regulates cell adhesion, signaling, and immune modulation by interacting with transmembrane receptors and modulating membrane fluidity. As a tumor-associated antigen, GM3 overexpression is observed in various malignancies, while its aberrant distribution contributes to neurological and metabolic disorders.

• Structure

GM3 consists of a ceramide backbone linked to a trisaccharide moiety (Neu5Acα2-3Galβ1-4Glc). Its amphipathic structure enables integration into the outer lipid bilayer, where the hydrophilic oligosaccharide extends into the extracellular space. The spatial arrangement of sialic acid residues governs interactions with receptors like epidermal growth factor receptor (EGFR) and integrins, making GM3 a key mediator of cellular crosstalk.

Fig.1 Representative structures of ganglioside GM3.¹

• Related Signaling Pathways

GM3 modulates signal transduction by organizing membrane microdomains and directly binding signaling molecules:

- EGFR Inhibition: GM3 binding to EGFR stabilizes its inactive conformation, suppressing tyrosine kinase activity and downstream MAPK/ERK pathways.

- Insulin Resistance: GM3 accumulation in adipocyte membranes disrupts insulin receptor clustering, impairing GLUT4 translocation and glucose uptake.

- Immune Evasion: Tumor-derived GM3 suppresses dendritic cell maturation and T-cell activation via Siglec-7/9 interactions.

• Associated Diseases

GM3 dysregulation is implicated in oncology, neurology, and metabolic syndromes:

- Cancer: Overexpressed in melanoma, breast, and ovarian cancers, GM3 promotes metastasis by enhancing integrin-mediated cell motility and immune evasion.

- Neurodegeneration: Elevated GM3 in brain lipid rafts correlates with amyloid-beta aggregation in Alzheimer's disease and α-synucleinopathy in Parkinson's disease.

- Diabetes: Adipose GM3 accumulation exacerbates systemic insulin resistance and metabolic inflammation.

Applications of GM3 Neutralizing Antibodies

• Oncology: Targeting Tumor Microenvironments

GM3 antibodies block metastasis by inhibiting integrin αvβ3 activation and reduce immunosuppressive signals in tumor-associated macrophages. In xenograft models, anti-GM3 therapy synergizes with checkpoint inhibitors to enhance T-cell infiltration.

• Metabolic Disease Research: Reversing Insulin Resistance

Neutralizing GM3 in adipocyte membranes restores insulin receptor autophosphorylation, offering a novel strategy for treating obesity-linked diabetes. In vivo studies demonstrate improved glycemic management and decreased hepatic steatosis.

• Neurological Therapeutics: Mitigating Proteinopathies

Anti-GM3 antibodies reduce amyloid-beta plaque burden by dissociating GM3-rich lipid rafts in neuronal membranes. In Parkinson's models, they attenuate α-synuclein oligomerization and neuroinflammation.

• Infectious Disease: Blocking Viral Entry

Enveloped viruses like influenza and SARS-CoV-2 utilize GM3-rich membranes for entry. Neutralizing antibodies prevent viral fusion by competitively binding host GM3, validated in pseudovirus neutralization assays.

• Diagnostic Development: Biomarker Validation

GM3-specific antibodies enable ultrasensitive detection in serum exosomes, serving as non-invasive biomarkers for early cancer detection or neurodegenerative disease monitoring.

Our Anti-GM3 Antibody Products

Creative Biolabs provides GM3-specific Neutra™ antibody products that help researchers to decode glycan-driven pathologies and accelerate therapeutic innovation. With rigorously validated specificity and unmatched functional performance, our antibodies are indispensable tools for oncology, neurology, and metabolic research. The GM3-specific antibodies are engineered for high selectivity and functional blocking. These antibodies:

- Neutralize Pathogenic GM3 Clusters: High-affinity binding disrupts GM3-receptor interactions, restoring EGFR signaling in cancers or insulin sensitivity in metabolic models.

- Enable Glycan-Specific Detection: Validated for flow cytometry and immunohistochemistry, they distinguish GM3 from structurally similar gangliosides (e.g., GM1).

- Support Therapeutic Development: Antibody-drug conjugates (ADCs) targeting GM3-expressing tumors show enhanced cytotoxicity in preclinical trials, while recombinant neutralizing antibodies inhibit viral entry mechanisms exploiting GM3-rich membranes.

Contact our team today to discuss customized solutions for your GM3-focused projects.

REFERENCE

1. Zhang, Jiaxu, et al. "Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies." Biomedicine & Pharmacotherapy 176 (2024): 116824. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.biopha.2024.116824